---
title: "Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294783340.md"
description: "A precision oncology company, Evexta Bio S.A., established by Truffle Capital, known for founding Abivax and Carvolix, revealed a clinical partnership and supply deal aimed at commencing a Phase 1b trial. The study will couple their primary investigational compound, rupitasertib, with Roche's investigational compound giredestrant, an SERD, focusing on treating ER+, HER2-, ESR1-m patients. This collaboration marks a significant step in the development of targeted therapies."
datetime: "2026-08-04T07:02:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294783340.md)
  - [en](https://longbridge.com/en/news/294783340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294783340.md)
generator: "portal-rs"
---

# Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer

A precision oncology company, Evexta Bio S.A., established by Truffle Capital, known for founding Abivax and Carvolix, revealed a clinical partnership and supply deal aimed at commencing a Phase 1b trial. The study will couple their primary investigational compound, rupitasertib, with Roche's investigational compound giredestrant, an SERD, focusing on treating ER+, HER2-, ESR1-m patients. This collaboration marks a significant step in the development of targeted therapies.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md)
- [Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion](https://longbridge.com/en/news/297692233.md)
- [12:49 ETSimcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660](https://longbridge.com/en/news/297813196.md)
- [04:00 ETSimcere Zaiming sluit exclusieve licentieovereenkomst met Roche voor wereldwijde ontwikkeling van SIM0660](https://longbridge.com/en/news/297751599.md)
- [Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentation](https://longbridge.com/en/news/297654775.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**